Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Shares Slide 9.3 Percent Despite 52-Percent Q1 Revenue Growth

This article has been corrected from a previous version. Adam Chazan does not cover Genaissance for Pacific Growth, and the reported cash burn rate of $3 million and total cash on hand were incomplete figures.


NEW YORK, May 3 (GenomeWeb News) - Shares in Genaissance sank more than 9.3 percent, or $.10, to $.98 in late-afternoon trading despite the company posting a 51-percent increase in total revenue and a 34-percent decline in net losses.


Total receipts for the three months ended March 31 increased to $5.6 million from $3.7 million year over year. Revenues from licensing and research were flat at $2.9 million, though receipts from lab services swelled to $2.7 million from $860,000 in the year-ago quarter.


Genaissance said it spent $3.3 million on R&D, down from $5 million during the first quarter 2004.


Net losses in the period fell to $3.1 million, or $.09 per basic share, from $4.7 million, or $.21 per basic share, year over year.


Genaissance said it had around $5.9 million in cash and equivalents as of March 31.


"There is also $1.3 million of non-cash charges, so the cash loss is only $1.7 million [per quarter]. And we added $2 million of cash at the end of the quarter," Ben Kaplan, the company's CFO, told GenomeWeb News. Genaissance's current cash on hand is about $8 million, said Kaplan.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more